Liver damage was detected (37.5%, 18/48) in SC patients despite the low levels of ALT and AST (below 50 IU/mL each). function during pathogenesis of liver disease. Disclosures: The following people have nothing to disclose: Birgit Schiller, Claudia Wegscheid, Laura Berkhout, Agnieszka E. Zarzycka, Ulrich Steinhoff, Nicole Fischer, Gisa Tiegs 731 Disparate Changes in LY341495 Adaptive Immunity in Systemic vs. Portal Venous Circulation, Across the Spectrum of HCV Associated Liver Disease and expression was maintained in cultured HSEC The expression of CD151 in HSEC was upregulated by stimulation with HepG2 supernatant and tumourigenic growth factors, such as hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF). We also found CD151 molecules clustering around adherent T cells following capture from physiological flow by HSEC monolayers Furthermore, function\blocking antibodies to CD151 significantly reduced adherence of T cells under flow conditions. Conclusion: We demonstrate, for the first time, the expression of CD151 on human sinusoidal endothelial cells and neovessels in a range of chronic liver diseases and HCC. We also demonstrate that CD151 in HSEC is maintained and can be upregulated by pro\tumourigenic factors and plays an important functional role in T cell adhesion to HSEC Taken together, these findings further our understanding of hepatic inflammation and lymphocyte recruitment to the liver, during chronic disease and carcinogenesis, and could form the basis of a potential therapeutic target. Disclosures: The following people have nothing to disclose: Daniel A. Patten, James C. Wadkin, Sivesh K. Kathir Kamarajah, Chris J. Weston, Shishir Shetty 737 ? Health gains and costs of HCV treatment: a cost effectiveness analysis of two different health policies scenarios simulated in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) real life cohort. Hepascore is a serum test that provides clinically useful data regarding the stage of liver fibrosis and subsequent clinical outcomes in chronic liver disease. The aim of this study was to determine if the change in Hepascore results over time (delta Hepascore) could accurately predict the change in risk of liver related death (LRD), hepatocellular carcinoma (HCC), liver decompensation (LD) and composite endpoint (LRD, HCC, LD) in HCV infection. 353 chronic hepatitis C patients who Mouse monoclonal to RAG2 attended the Department of Hepatology, Sir Charles Gairdner Hospital, Western Australia from 1992 to 2012 and had two or more Hepascore tests performed were studied The ability of a baseline and delta Hepascore test to predict liver related outcomes was assessed using univariate and multivariate Cox regression, AUROC and Kaplan\Meier analysis. During 1944 patient years follow up 28 (7.9%) developed hepatocellular carcinoma, liver decompensation, and/or liver LY341495 related death. Baseline Hepascore (p 0.001) and delta Hepascore (p=0.044) were independently associated with the composite endpoint A baseline Hepascore 0.75 was associated with a significant increase in LRD (p=0.001), LD (p=0.004) and HCC (p=0.001). Patients with a baseline Hepascore 0.75 and a subsequent improvement in delta Hepascore ( \0.1) had a significantly decreased risk of LRD (p=0.048), LD (p=0.04) and composite endpoint (p=0.004) compared to those with a baseline Hepascore of 0.75 and a stable Hepascore value (delta 0.1) or a deteriorated Hepascore value LY341495 (delta 0.1) The optimum time interval between Hepascore checks was determined by comparing those with improved delta Hepascore to those with stable or worse delta Hepascore The combination of baseline Hepascore and delta Hepascore was significantly predictive of improved liver related outcomes only when the time between checks was 1 year (p=0.03). This study showed that improved Hepascore ideals were significantly associated with reduced rates of liver\related mortality and morbidity These findings possess implications for patient management following HCV eradication and may determine the time for reduced need for variceal and HCC screening. Disclosures: Angus W. Jeffrey \ Patent Held/Filed: UWA Leon A. Adams \ Patent Held/Filed: Pursuit diagnostics The following people have nothing to disclose: Yi Huang, Bastiaan de Boer, Gerry C. MacQuillan, David J. Speers, John Joseph, Gary P. Jeffrey 749 Recognition of Patient Organizations Previously Not Candidates for Interferon Therapy for Chronic Hepatitis C and Implications for Planning and Budgeting for Treatment with Current Regimens agglutinin\positive Mac pc\2 binding protein (M2BPGi) was reported like a noninvasive marker of liver fibrosis and a predictor of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) individuals. This study targeted to assess time\dependent associations between M2BPGi and HCC development in.